AMIVANTAMAB-VMJW

Guidelines for Use

GUIDELINES FOR USE

 

Our guideline name AMIVANTAMAB-VMJW (Rybrevant) requires the following rule(s) be met for approval:

1. You have locally advanced or metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to nearby tissue, lymph nodes, or other parts of the body)
2. You are 18 years of age or older
3. If you have epidermal growth factor receptor (EGFR: type of protein) exon 19 deletions or exon 21 L858R substitution mutations (abnormal changes in a type of gene), approval also requires ONE of the following:
   1. Your mutation is detected by a Food and Drug Administration (FDA)-approved test AND Rybrevant will be used in combination with lazertinib (Lazcluze)
   2. Rybrevant will be used in combination with carboplatin and pemetrexed AND your disease has progressed while on or after epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor therapy (such as Tagrisso [osimertinib], Tarceva [erlotinib], Iressa [gefitinib], Gilotrif [afatinib])
4. If you have epidermal growth factor receptor (EGFR: type of protein) exon 20 insertion mutations (abnormal changes in a type of gene), as detected by a Food and Drug Administration (FDA)-approved test, approval also requires you meet ONE of the following:
   1. Rybrevant will be used in combination with carboplatin and pemetrexed
   2. Rybrevant will be used as a single agent AND your disease has progressed on or after platinum-based chemotherapy (such as cisplatin, carboplatin)
      1. Daratumumab-hyaluronidase-fihj and dexamethasone
      2. Isatuximab and dexamethasone